# Amgen vs Novartis: valuation, size and margins compared

URL: https://funkfolio.com/compare/amgn-vs-nvs

> Amgen ($247.7B, P/E 26.8) and Novartis ($300.5B, P/E 30.6) compared: size, valuation, margins, debt, cash and price change.

---

## Amgen vs Novartis

Amgen (AMGN), health care, and Novartis (NVS), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Novartis is worth $300.5B on the stock market and Amgen $247.7B: Novartis is valued at 21% more. Amgen trades at 26.8 times earnings and Novartis at 30.6; operating margins in their latest fiscal years were 24.7% and 32.4%. Over the past year Amgen's share price has moved +34.4% and Novartis's +25.1%.

### Key facts

- **Amgen market value:** $247.7B
- **Novartis market value:** $300.5B
- **Amgen P/E:** 26.8
- **Novartis P/E:** 30.6
- **Amgen revenue:** $36.8B FY to 2025-12-31
- **Novartis revenue:** $54.5B FY to 2025-12-31
- **Superinvestors holding both:** 3

Market values as of 18 Nov 2026, 03:50 UTC.

Amgen vs Novartis: every measure side by side

| Measure | Amgen | Novartis |
| --- | --- | --- |
| Sector | Health Care | Health Care |
| Country | United States | Switzerland |
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size |  |  |
| Market cap | $247.7B lower | $300.5B higher |
| Revenue | $36.8B lower | $54.5B higher |
| Earnings | $7.7B lower | $14B higher |
| Employees | 31,500 lower | 75,267 higher |
| Total assets | $90.6B lower | $110.9B higher |
| Valuation |  |  |
| P/E | 26.8 lower | 30.6 higher |
| P/S | 6.7 higher | 5.5 lower |
| P/B | 17.3 | — |
| Dividend yield | 2.15% | — |
| Profitability |  |  |
| Operating margin | 24.7% lower | 32.4% higher |
| Balance sheet |  |  |
| Net assets | $8.7B lower | $46.1B higher |
| Total liabilities | $81.9B higher | $64.4B lower |
| Total debt | $54.6B higher | $28.7B lower |
| Cash on hand | $9.1B lower | $11.4B higher |
| Price change |  |  |
| Today | -0.95% lower | -0.67% higher |
| 1 year | +34.4% higher | +25.1% lower |

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

### Share price over one year

Each company's share price rebased to 100 on Nov 17, 2025, so the two lines start together. Price only: dividends are not included. Last: Amgen 134.0, Novartis 121.0.

- Amgen (AMGN)
- Novartis (NVS)

Amgen and Novartis share prices over one year, rebased to 100: Amgen ends at 134.0, Novartis at 121.0.

**The chart as a table**

Month-end share prices rebased to 100

| Month end | AMGN | NVS |
| --- | --- | --- |
| Nov 28, 2025 | 101.1 | 99.1 |
| Dec 31, 2025 | 95.8 | 104.8 |
| Jan 30, 2026 | 100.0 | 113.0 |
| Feb 27, 2026 | 113.6 | 128.2 |
| Mar 31, 2026 | 103.0 | 116.1 |
| Apr 30, 2026 | 101.3 | 112.4 |
| May 29, 2026 | 98.6 | 114.2 |
| Jun 30, 2026 | 106.0 | 119.1 |
| Jul 31, 2026 | 112.7 | 118.7 |
| Aug 31, 2026 | 125.8 | 115.6 |
| Sep 30, 2026 | 123.4 | 108.4 |
| Oct 30, 2026 | 136.4 | 122.2 |
| Nov 17, 2026 | 134.0 | 121.0 |

### Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

#### Both (3)

- [Primecap team](https://funkfolio.com/gurus/primecap) 1.5% / 0.6%
- [Ken Fisher](https://funkfolio.com/gurus/ken-fisher) 0.2% / 0.7%
- [Dodge & Cox team](https://funkfolio.com/gurus/dodge-and-cox) &lt;0.1% / 0.1%

#### Amgen only (7)

- [Bill Smead](https://funkfolio.com/gurus/bill-smead) 5.3%
- [Howard Gleicher](https://funkfolio.com/gurus/howard-gleicher) 2.6%
- [Josef Lakonishok](https://funkfolio.com/gurus/josef-lakonishok) 0.4%
- [David Shaw (founder)](https://funkfolio.com/gurus/david-shaw) 0.3%
- [Fred DiSanto](https://funkfolio.com/gurus/fred-disanto) 0.2%
- [Ken Griffin](https://funkfolio.com/gurus/ken-griffin) 0.1%
- [Mairs & Power team](https://funkfolio.com/gurus/mairs-and-power) &lt;0.1%

#### Novartis only (10)

- [Tweedy, Browne team](https://funkfolio.com/gurus/tweedy-browne) 0.8%
- [Brandon Haley](https://funkfolio.com/gurus/brandon-haley) 0.4%
- [Larry Robbins](https://funkfolio.com/gurus/larry-robbins) 0.3%
- [Thomas Kahn](https://funkfolio.com/gurus/thomas-kahn) 0.3%
- [Andrew Spokes](https://funkfolio.com/gurus/farallon) 0.2%
- [Charles Brandes (founder)](https://funkfolio.com/gurus/charles-brandes) 0.2%
- [Jeremy Grantham (co-founder)](https://funkfolio.com/gurus/jeremy-grantham) 0.1%
- [Lee Ainslie](https://funkfolio.com/gurus/lee-ainslie) &lt;0.1%
- [Murray Stahl](https://funkfolio.com/gurus/murray-stahl) &lt;0.1%
- [Rajiv Jain](https://funkfolio.com/gurus/rajiv-jain) &lt;0.1%

Percentages are each holding's share of that investor's reported portfolio (under "Both": Amgen / Novartis). [Who owns AMGN](https://funkfolio.com/stock/AMGN/superinvestors) · [Who owns NVS](https://funkfolio.com/stock/NVS/superinvestors)

### More on Amgen

- [Amgen (AMGN) stock page](https://funkfolio.com/stock/AMGN)
- [Amgen market cap](https://funkfolio.com/stock/AMGN/market-cap)
- [Amgen revenue](https://funkfolio.com/stock/AMGN/revenue)
- [Amgen P/E ratio](https://funkfolio.com/stock/AMGN/pe-ratio)
- [Amgen operating margin](https://funkfolio.com/stock/AMGN/operating-margin)
- [Amgen total debt](https://funkfolio.com/stock/AMGN/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### More on Novartis

- [Novartis (NVS) stock page](https://funkfolio.com/stock/NVS)
- [Novartis market cap](https://funkfolio.com/stock/NVS/market-cap)
- [Novartis revenue](https://funkfolio.com/stock/NVS/revenue)
- [Novartis P/E ratio](https://funkfolio.com/stock/NVS/pe-ratio)
- [Novartis operating margin](https://funkfolio.com/stock/NVS/operating-margin)
- [Novartis total debt](https://funkfolio.com/stock/NVS/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### Further comparisons

#### Amgen against its closest peers

- [Amgen vs Thermo Fisher Scientific](https://funkfolio.com/compare/amgn-vs-tmo)
- [Amgen vs Gilead Sciences](https://funkfolio.com/compare/amgn-vs-gild)
- [Amgen vs AstraZeneca](https://funkfolio.com/compare/amgn-vs-azn)

#### Novartis against its closest peers

- [Novartis vs AstraZeneca](https://funkfolio.com/compare/azn-vs-nvs)
- [Novartis vs UnitedHealth Group](https://funkfolio.com/compare/nvs-vs-unh)
- [Novartis vs Merck & Co](https://funkfolio.com/compare/mrk-vs-nvs)
- [Novartis vs Thermo Fisher Scientific](https://funkfolio.com/compare/nvs-vs-tmo)

### Learn

- [What market capitalization is and is not](https://funkfolio.com/learn/markets/market-capitalization)
- [P/E ratio explained](https://funkfolio.com/learn/stocks/pe-ratio)
- [Market cap vs enterprise value](https://funkfolio.com/learn/markets/market-cap-vs-enterprise-value)

### Questions and answers

**Which is bigger, Amgen or Novartis?**

By market value, Novartis is the larger: $300.5B against $247.7B for Amgen. By revenue in its latest fiscal year, Novartis is the larger: $54.5B against $36.8B for Amgen.

**Which has the higher P/E ratio?**

Novartis: 30.6, against 26.8 for Amgen. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

**Which has the higher operating margin?**

Novartis: 32.4%, against 24.7% for Amgen. Operating margin is operating income as a share of revenue in the latest fiscal year.

**Which has more debt?**

Amgen: $54.6B, against $28.7B for Novartis. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

**Which superinvestors own both Amgen and Novartis?**

In their latest 13F filings, Primecap team, Ken Fisher and Dodge & Cox team hold both.

### Cite this page

Funkfolio, “Amgen vs Novartis”, data as of 18 November 2026. https://funkfolio.com/compare/amgn-vs-nvs

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.
